Demonstrates improved myocardial repair through magnetically labeled extracellular vesicles in mouse hearts, suggesting new theranostic applications.
This study aims to develop magnetically labeled iPSC-derived extracellular vesicles (magneto-EVs) for MRI/MPI and myocardial repair in a theranostic manner. Using optimized electroporation and purification protocols, we prepared magneto-EVs with high SuperSPIO20 loading efficiency (1.77 ng Fe/10? EVs) and well-preserved therapeutic effects. In vitro MPI results reveal that the detectability of magneto-EVs is ~1 × 109 EVs/mL. In vivo MPI shows that MPI can detect magneto-iPSC-EVs injected intramyocardially in mouse hearts for up to 7 days following myocardial infarction. MPI quantification showed that 32% of injected EVs remained in the heart after 24 hours, with a further ~50% decrease by day 7, indicating progressive clearance or biodegradation of magneto-EVs from the injected site. Despite this low retention and rapid clearance, magneto-EVs led to significant improvement in left ventricular ejection fraction (37.3% increase) and scar formation (61.0% reduction). This theranostic EV imaging platform enables quantitative MPI monitoring of EV delivery and predicting therapeutic outcomes.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: